“Evaluation of the efficacy and safety of Melagenina Plus® in the treatment of patients with vitiligo”. Phase IV

Inclusion criteria

1. Patients with a clinical and histological diagnosis compatible with vitiligo.
2. Patients of any sex and age between 2 and 70 years, both inclusive.
3. Patients with depigmented areas between 1 and 40%.
4. Adult patient, mother, father or legal guardian who gives consent to participate in the study in writing. Patients between 2 and 11 years old (including both ages) who give their consent. Patients between 12 and 18 years old (both ages included) who grant their IC together with the responsible adult.

Exclusion criteria

1. Pregnant or lactating patients.
2. Patients with associated infectious skin disease at the time of inclusion.
3. Patients with severe chronic disease requiring steroid treatment.
4. Patients with psychiatric illnesses that could limit adherence to the requirements of the trial.
5. Patients with a known history of immunosuppression.
6. Patients who in the 45 days prior to their assessment for inclusion in the study have received any treatment for vitiligo: immunosuppressants, Melagenina Plus, (topical or systemic corticosteroids, cyclosporine, phototherapy with UVA, photochemotherapy (psoralens and UVA), cytostatics .
7. Patients with oral or systemic contraceptive treatment.
8. Patients with chronic depigmentary dermatitis or endocrine diseases that cause pigmentation disorders (mainly Addison’s disease, thyroid and hypopituitarism diseases).